Type 2 diabetes remission: economic evaluation of the DiRECT/Counterweight‐Plus weight management programme within a primary care randomized controlled trial

Aim The Counterweight‐Plus weight management programme achieved 46% remission of Type 2 diabetes at 1 year in the Di RECT trial. We estimated the implementation costs of the Counterweight‐Plus programme and its 1‐year cost‐effectiveness in terms of diabetes remission, compared with usual care, from the UK National Health Service ( NHS ) perspective. Methods Within‐trial total costs included programme set‐up and running costs (practitioner...